Oura announced today that it has confidentially submitted a draft registration statement to the Securities and Exchange Commission for an initial public offering. The number of shares and the price are undetermined. What is known is what the company has said in public: a valuation of about $11 billion at its financing last fall, 5.5 million rings sold, a target of $1.5 billion in revenue this year, a $5.99-a-month membership, and a boilerplate line that the ring is not a medical device. We have written about this company twice — in December 2024, when its valuation implied a shift from measuring sleep to diagnosing bodies, and in October, when it started selling blood panels. Today's filing is the next step, and it comes with a gift for readers of this site.
What a prospectus has to say. A private company tells you what it wants to. A public one has to tell you, under penalty, how much of its revenue is hardware versus subscription, how many paying members it has and how many it loses, what it spends to acquire each one, what it is being sued over, and what it believes the risks to its business are — including, if regulators are a risk, which ones. The wearable industry has never had to publish those numbers. When the public filing arrives, it will show what the ring business actually is: a device, or a subscription to worry. We will read every page and report which.
Ben’s takeI have read a lot of S-1s and the risk-factors section is where the marketing goes to confess. Expect to learn what fraction of members renew, how much growth depends on the blood-test and membership upsells we have been describing, and whether the company considers the FDA's line between wellness and medicine a threat. Nothing in the pitch deck has to be true. Everything in the prospectus does. That makes this the most useful document the industry will publish this year, and it is free.
Loree’s takeMy interest is one line in the filing: the sentence that says the ring is not a medical device. It will be there, because the lawyers require it. It will sit a few pages from the sentence that says members use the product to understand their health. The gap between those two sentences is where my patients live, and a public company has to put both on the record.
Why it matters to a recovering optimizer. You are about to be able to read, in the company's own words and under the company's own liability, what the thing on your finger is for and how it makes money. Read it when it comes. Compare it to the ads. The difference is what this site is about.
When a health product goes public, read the risk factors before the ads. The company has to be honest in only one of them.